Content deleted Content added
Citation bot (talk | contribs) Removed parameters. | Use this bot. Report bugs. | #UCB_CommandLine |
Update treatment options |
||
Line 103:
===Depression===
The National Institutes of Health estimates depression medications work for 60 percent to 70 percent of people who take them.<ref>{{cite book | url=https://www.ncbi.nlm.nih.gov/books/NBK20369/|title= Information about Mental Illness and the Brain|year= 2007|publisher= National Institutes of Health (US)}}</ref><ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.</ref> It is approved as a Class II medical device under the "''de novo'' pathway".<ref>Michael Drues, for Med Device Online. 5 February 2014 [http://www.meddeviceonline.com/doc/secrets-of-the-de-novo-pathway-part-why-aren-t-more-device-makers-using-it-0001 Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?]</ref><ref name=2015revPain>{{cite journal | vauthors = Schwedt TJ, Vargas B | title = Neurostimulation for Treatment of Migraine and Cluster Headache | journal = Pain Medicine | volume = 16 | issue = 9 | pages = 1827–1834 | date = September 2015 | pmid = 26177612 | pmc = 4572909 | doi = 10.1111/pme.12792 }}</ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.<ref>{{Cite web |title="Depression: let's talk" says WHO, as depression tops list of causes of ill health |url=https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health |access-date=2022-08-10 |website=www.who.int |language=en}}</ref> In a 2012 study, TMS was found to improve depression significantly in 58 percent of patients and provide complete remission of symptoms in 37 percent of patients.<ref>{{cite journal |vauthors=Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA |title=Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice |journal=Depress Anxiety |volume=29 |issue=7 |pages=587–96 |date=July 2012 |pmid=22689344 |doi=10.1002/da.21969 |s2cid=22968810 |url=}}</ref>
== Obsessive–Compulsive Disorder (OCD) ==
In August 2018, the US Food and Drug Administration (US FDA) authorized the use of TMS developed by the [[Israel]]i company [[Brainsway]] in the treatment of [[obsessive–compulsive disorder]] (OCD).<ref>{{cite web |
In 2020, US FDA authorized the use of TMS developed by the U.S. company MagVenture Inc. in the treatment of OCD.<ref>{{Cite web |title=MagVenture receives FDA clearance for OCD {{!}} Clinical TMS Society |url=https://www.clinicaltmssociety.org/news/2020-08/magventure-receives-fda-clearance-ocd-0 |access-date=2023-10-11 |website=www.clinicaltmssociety.org}}</ref>
In 2023, US FDA authorized the use of TMS developed by the U.S. company Neuronetics Inc. in the treatment of OCD.
====Other neurological areas====
In the [[European Economic Area]], various versions of Deep TMS H-coils have [[CE marking]] for [[Alzheimer's disease]],<ref name=OCD/> [[autism]],<ref name=OCD/> [[bipolar disorder]],<ref name=Chronicpain/> [[epilepsy]],<ref>{{cite journal | vauthors = Gersner R, Oberman L, Sanchez MJ, Chiriboga N, Kaye HL, Pascual-Leone A, Libenson M, Roth Y, Zangen A, Rotenberg A | display-authors = 6 | title = H-coil repetitive transcranial magnetic stimulation for treatment of temporal lobe epilepsy: A case report | journal = Epilepsy & Behavior Case Reports | volume = 5 | issue = Supplement C | pages = 52–56 | date = 2016-01-01 | pmid = 27114902 | pmc = 4832041 | doi = 10.1016/j.ebcr.2016.03.001 }}</ref> chronic pain,<ref name=Chronicpain/> [[major depressive disorder]],<ref name=Chronicpain/> [[Parkinson's disease]],<ref name="Chou YH 2014"/><ref>{{cite journal | vauthors = Torres F, Villalon E, Poblete P, Moraga-Amaro R, Linsambarth S, Riquelme R, Zangen A, Stehberg J | display-authors = 6 | title = Retrospective Evaluation of Deep Transcranial Magnetic Stimulation as Add-On Treatment for Parkinson's Disease | journal = Frontiers in Neurology | volume = 6 | pages = 210 | date = 2015-10-26 | pmid = 26579065 | pmc = 4620693 | doi = 10.3389/fneur.2015.00210 | doi-access = free }}</ref> [[post-traumatic stress disorder]] (PTSD),<ref name=Chronicpain/> [[schizophrenia]] (negative symptoms)<ref name=Chronicpain>{{cite web |url=http://www.medgadget.com/2012/07/brainsways-deep-tms-eu-cleared-for-neuropathic-chronic-pain.html|title= Brainsway's Deep TMS EU Cleared for Neuropathic Chronic Pain|date= July 3, 2012 |publisher= medGadget |access-date=December 16, 2013}}</ref> and to aid smoking cessation.<ref name=OCD>{{cite news |url=http://www.medicaldevice-network.com/news/newsbrainsway-reports-positive-deep-tms-system-trial-data-ocd|title= Brainsway reports positive Deep TMS system trial data for OCD|newspaper= Medical Device Network|date= September 6, 2013 |publisher= Medicaldevice-network |access-date= December 16, 2013}}</ref> One review found tentative benefit for cognitive enhancement in healthy people.<ref>{{cite journal | vauthors = Luber B, Lisanby SH | title = Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS) | journal = NeuroImage | volume = 85 Pt 3 | issue = 3 | pages = 961–970 | date = January 2014 | pmid = 23770409 | pmc = 4083569 | doi = 10.1016/j.neuroimage.2013.06.007 }}</ref>
▲In August 2018, the US Food and Drug Administration authorized the use of TMS developed by the [[Israel]]i company [[Brainsway]] in the treatment of [[obsessive–compulsive disorder]] (OCD).<ref>{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm617244.htm|title=FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder|website=[[Food and Drug Administration]]|date=2020-02-20}}</ref>
===Coverage by health services and insurers===
| |||